AMBAR is an international multi-center randomized double blind-designed clinical trial aimed at evaluating whether the progression of Alzheimer's disease could be stabilized through periodic plasma exchange with albumin replacement.
STAY TUNED!
Sign in if you would like to stay updated about progression of the AMBAR clinical program and Grifols Research Programs on Alzheimer's (presentations of results at medical congresses, scientific publications, etc…).
DATA PROTECTION INFORMATION
Data controller
Grifols, S.A.
Purpose
To send you by e-mail scientific and educational information related to AMBAR clinical program and Grifols Research Programs on Alzheimer's.
Legal basis
Consent
Recipients
Grifols' group companies
Rights
To access, rectify and erase personal data, as well as other rights detailed in the additional information section.
Additional information
For additional information on how Grifols processes your personal data please click here
BG/ALB/0519/0034